The purpose of this study is to test the safety and efficacy of RBX2660 in preventing recurrent episodes of CDI measured at 8 weeks after treatment.
Visit ClinicalTrials.gov for more information.
Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.